Japanese Takeda Pharmaceutical Firm Plans to Expand in Saudi Arabia

Japanese Takeda Pharmaceutical Firm Plans to Expand in Saudi Arabia

The Tokyo-headquartered company has placed its focus on providing products to the Kingdom in areas such as oncology, rare diseases, gastroenterology, and plasma-derived therapies.

Rodrigo Rodriguez, Takeda’s general manager for the Middle East, told Arab News: “From 2021 on, we expect growth in the Kingdom driven by these highly innovative inline products and the launches that we anticipate in key therapeutic areas.”

Over the next two years, the research-based firm plans to launch five new products in Saudi Arabia: Adynovate for the blood-clotting disorder hemophilia; Firazyr for acute attacks of hereditary angioedema (HAE), an allergic reaction resulting in skin swelling; HyQvia, which helps boost the immune system; and two other drugs for the treatment of rare and serious types of cancer.